Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.

Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.

We conducted a Phase I dose escalation trial of ADVAX, a DNA-based candidate HIV-1 vaccine expressing Clade C/B' env, gag, pol, nef, and tat genes. Sequences were derived from a prevalent circulating recombinant form in Yunnan, China, an area of high HIV-1 incidence. The objective was to evalua...

Full description

Bibliographic Details
Main Authors: Sandhya Vasan, Sarah J Schlesinger, Yaoxing Huang, Arlene Hurley, Angela Lombardo, Zhiwei Chen, Soe Than, Phumla Adesanya, Catherine Bunce, Mark Boaz, Rosanne Boyle, Eddy Sayeed, Lorna Clark, Daniel Dugin, Claudia Schmidt, Yang Song, Laura Seamons, Len Dally, Martin Ho, Carol Smith, Martin Markowitz, Josephine Cox, Dilbinder K Gill, Jill Gilmour, Michael C Keefer, Patricia Fast, David D Ho
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2799527?pdf=render

Internet

http://europepmc.org/articles/PMC2799527?pdf=render

Similar Items